ALXN News Alert Alexion Pharmaceuticals (ALXN) 165.86 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexion Pharmaceuticals (ALXN) 165.86 $ALXN

Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - 2 hrs 30 mins ago
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....

Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions

After Yesterday's Rally of 6.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:55PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $158.67 to a high of $168.98. Yesterday, the shares gained 6.3%, which took the trading range above the 3-day high of $163.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...

Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...

Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...

Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 24, 10:05AM CDT
Auxilium Pharmaceuticals' (AUXL) shares soared almost 45% on a $2.2 billion acquisition proposal from Endo.

Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical

Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:20PM CDT
Recently, Zacks Investment Research upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).

IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...

Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function
Business Wire - Fri Sep 19, 2:45AM CDT
Alexion Pharmaceuticals today announced that researchers presented data from the open-label extension phases of two Phase 2 studies of asfotase alfa, an investigational enzyme replacement therapy, in paediatric patients with hypophosphatasia (HPP).(1,2) In the ongoing studies, researchers observed sustained improvements in growth, strength, physical function, and other key measures in paediatric patients with HPP who were treated with asfotase alfa for up to three years. HPP is a genetic, chronic and progressive ultra-rare metabolic disease that can lead to ongoing damage to multiple vital organs, destruction and deformity of bones, and premature death.(3-7) Data were presented today at the 53rd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Dublin, Ireland, following a presentation of similar data earlier this month at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting.(8,9)

Alexion Strengthens and Broadens Its Executive Leadership Team
Business Wire - Wed Sep 17, 6:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced key measures to strengthen and broaden its executive leadership team in line with the Company's expanding global mission to develop and commercialize life-transforming therapies for patients with severe and rare disorders.

Alexion Pharmaceuticals Falls 1.41% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 4:21PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $157.30 to a high of $162.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $161.00 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...

Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years
Business Wire - Sun Sep 14, 4:30PM CDT
---- Patients Receiving Asfotase Alfa Also Had Significantly Improved Ventilator-Free Survival Compared to Historical Controls --

Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...

Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.

Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 39

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 43

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 179

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 156

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 24

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 82

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading

Top 5 Most Recently Viewed Articles

Globeleq Strengthens Leadership with Alasdair Martin's Appointment

Updated Category News Views 169

Globeleq Welcomes Alasdair Martin as Director of Private Customer Solutions Globeleq, a prominent independent power company in Africa, has appointed Alasdair Martin to the crucial role of Director of Private Customer Solutions. This appointment is a strategic move that aligns with the company's vision for growth through innovation and sustainable energy transformation in...

Continue Reading
Orthofix Medical's Q4 2026 Earnings: Unpacking The Numbers

Updated Category News Views 186

Earnings Breakdown Let's get into the nitty-gritty of Orthofix Medical's earnings for Q4 of 2026. Rollercoaster ride, anyone? They posted an earnings-per-share (EPS) of $0.24, which is a solid beat over the $0.12 consensus estimate. That's a clean 100% overcall—on paper, that's the kind of news that gets you smiling on your way to the bank. Honestly, an earnings double...

Continue Reading
bioAffinity Technologies Achieves Milestone with CyPath® Lung Test

Updated Category News Views 106

bioAffinity Technologies Celebrates Initial Success of CyPath® Lung b>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), dedicated to advancing noninvasive cancer detection and lung disease diagnostics, has unveiled remarkable outcomes from its recent pilot marketing program for the CyPath® Lung test. Focused on enhancing patient care, the Texas beta launch has seen...

Continue Reading
Hamilton Beach Brands Reports Strong Q3 Performance for 2024

Updated Category News Views 145

Company Overview Hamilton Beach Brands Holding Company (NYSE: HBB) is an established leader in the design, marketing, and distribution of a variety of small electric household appliances and specialty products. With a portfolio that includes well-known consumer brands such as Hamilton Beach® and Proctor Silex®, the company continues its mission to enhance daily living...

Continue Reading
Melexis Expands Treasury Share Holdings with Recent Buyback

Updated Category News Views 155

Melexis Share Buy-Back Program Update Melexis is excited to share an update regarding its ongoing share buy-back program, originally announced several months ago. This initiative aims to enhance shareholder value and stabilize stock prices in today’s dynamic market environment. As part of this program, Melexis has recently engaged in notable share purchases on Euronext...

Continue Reading